Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;18(3):414-22.
doi: 10.1016/j.bbmt.2011.08.016. Epub 2011 Aug 26.

Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation

Ron Ram  1 , Barry Storer, Marco Mielcarek, Brenda M Sandmaier, David G Maloney, Paul J Martin, Mary E D Flowers, Bee K Chua, Marcello Rotta, Rainer Storb
Affiliations

Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation

Ron Ram et al. Biol Blood Marrow Transplant. 2012 Mar.

Abstract

To determine whether calcineurin inhibitor (CNI) blood concentrations within the first month after allogeneic hematopoietic cell transplantation (HCT) correlated with the incidence of graft-versus-host disease (GVHD) and other outcomes, we retrospectively analyzed data from 1181 patients with hematologic malignancies who had HCT from HLA-matched related (n = 634) or unrelated (n = 547) donors at a single institution between 2001 and 2009. After myeloablative HCT (n = 774), higher CNI concentrations were not associated with lower risks of acute or chronic GVHD (aGVHD, cGVHD). After nonmyeloablative HCT (n = 407), higher cyclosporine concentrations were associated with decreased risks of grade 2-4 and 3-4 aGVHD (hazard ratio [HR] per 100 ng/mL change in cyclosporine concentrations, 0.7; 95% confidence interval [CI], 0.6-0.82; and HR, 0.66, 95% CI, 0.49-0.9, respectively), nonrelapse mortality (HR, 0.6, 95% CI, 0.41-0.88), and overall mortality (HR, 0.83, 95% CI, 0.71-0.99). Cyclosporine concentrations were not associated with risks of cGVHD and recurrent malignancy after nonmyeloablative HCT. Among patients given tacrolimus after nonmyeloablative HCT, a similar trend of CNI-associated GVHD-protection was observed. Higher CNI concentrations were not associated with apparent renal toxicity. We conclude that higher cyclosporine concentrations relatively early after nonmyeloablative HCT confer protection against aGVHD that translates into reduced risks of nonrelapse and overall mortality.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Association of mean week 2 CSP (A and B) and TAC (C and D) concentrations with the cumulative incidence of grade 2–4 (A and C) and grade 3–4 (B and D) acute GVHD after HCT with nonmyeloablative conditioning. CNI concentrations were divided according to quartiles.
Figure 2
Figure 2
Correlation of mean week 2 CNI concentrations in patients treated with CSP (A and C) or TAC (B and D) with the maximal change in GFR during the first 4 weeks after HCT with myeloablative conditioning (A and B) or nonmyeloablative conditioning (C and D).
See this image and copyright information in PMC

Comment in

References

    1. Cutler C, Antin JH. Manifestations and treatment of acute graft-versus-host disease. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG, editors. Thomas’ Hematopoietic Cell Transplantation. Oxford, UK: Wiley-Blackwell; 2009. pp. 1287–1303.
    1. Gratwohl A, Hermans J, Apperley J, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia (Review) Blood. 1995;86:813–818. - PubMed
    1. Storb R, Deeg HJ, Farewell V, et al. Marrow transplantation for severe aplastic anemia: Methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood. 1986;68:119–125. - PubMed
    1. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729–735. - PubMed
    1. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host-disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92:2303–2314. - PubMed

Publication types

MeSH terms